IDXX vs ZTS vs HSIC vs ELAN vs ANIP

For growth investors, ANI Pharmaceuticals, Inc.

(ANIP) is the stronger pick with 43. 8% revenue growth year-over-year, versus 2. 3% for Zoetis Inc. (ZTS). Zoetis Inc. (ZTS) offers the better valuation at 13. 8x trailing P/E (11. 9x forward), making it the more compelling value choice. Analysts rate IDEXX Laboratories, Inc. (IDXX) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Zoetis Inc.

(ZTS) is the cheapest at 13. 8x versus IDEXX Laboratories, Inc. at 42. 8x. On forward P/E, ANI Pharmaceuticals, Inc. is actually cheaper at 9. 0x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Zoetis Inc. wins at 0. 99x versus Henry Schein, Inc. 's 4. 20x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, ANI Pharmaceuticals, Inc.

(ANIP) delivered a total return of +148. 8%, compared to -46. 9% for Zoetis Inc. (ZTS). Over 10 years, the gap is even starker: IDXX returned +542. 3% versus ELAN's -34. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), ANI Pharmaceuticals, Inc.

(ANIP) is the lower-risk stock at 0. 56β versus Elanco Animal Health Incorporated's 1. 46β — meaning ELAN is approximately 160% more volatile than ANIP relative to the S&P 500. On balance sheet safety, ANI Pharmaceuticals, Inc. (ANIP) carries a lower debt/equity ratio of 60% versus 3% for Zoetis Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ANI Pharmaceuticals, Inc.

(ANIP) is pulling ahead at 43. 8% versus 2. 3% for Zoetis Inc. (ZTS). On earnings-per-share growth, the picture is similar: ANI Pharmaceuticals, Inc. grew EPS 419. 2% year-over-year, compared to -169. 1% for Elanco Animal Health Incorporated. Over a 3-year CAGR, ANIP leads at 40. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Zoetis Inc.

(ZTS) is the more profitable company, earning 28. 2% net margin versus -4. 9% for Elanco Animal Health Incorporated — meaning it keeps 28. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ZTS leads at 38. 0% versus 5. 3% for ELAN. At the gross margin level — before operating expenses — ZTS leads at 70. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Zoetis Inc. (ZTS) is the more undervalued stock at a PEG of 0. 99x versus Henry Schein, Inc. 's 4. 20x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, ANI Pharmaceuticals, Inc. (ANIP) trades at 9. 0x forward P/E versus 38. 3x for IDEXX Laboratories, Inc. — 29. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ZTS: 61. 3% to $133. 57.

In this comparison, ZTS (2.

4% yield) pays a dividend. IDXX, HSIC, ELAN, ANIP do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Zoetis Inc.

(ZTS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 88), 2. 4% yield). Both have compounded well over 10 years (ZTS: +97. 8%, ELAN: -34. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: IDXX is a mid-cap quality compounder stock; ZTS is a mid-cap deep-value stock; HSIC is a small-cap quality compounder stock; ELAN is a mid-cap quality compounder stock; ANIP is a small-cap high-growth stock. ZTS pays a dividend while IDXX, HSIC, ELAN, ANIP do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.